CA3052503A1 - Methods of treating influenza - Google Patents

Methods of treating influenza Download PDF

Info

Publication number
CA3052503A1
CA3052503A1 CA3052503A CA3052503A CA3052503A1 CA 3052503 A1 CA3052503 A1 CA 3052503A1 CA 3052503 A CA3052503 A CA 3052503A CA 3052503 A CA3052503 A CA 3052503A CA 3052503 A1 CA3052503 A1 CA 3052503A1
Authority
CA
Canada
Prior art keywords
influenza
virus
influenza virus
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3052503A
Other languages
English (en)
French (fr)
Inventor
Gary Ewart
Carolyn Luscombe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotron Ltd
Original Assignee
Biotron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900385A external-priority patent/AU2017900385A0/en
Application filed by Biotron Ltd filed Critical Biotron Ltd
Publication of CA3052503A1 publication Critical patent/CA3052503A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3052503A 2017-02-08 2018-02-07 Methods of treating influenza Pending CA3052503A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017900385A AU2017900385A0 (en) 2017-02-08 Methods of treating influenza
AU2017900385 2017-02-08
PCT/AU2018/050085 WO2018145148A1 (en) 2017-02-08 2018-02-07 Methods of treating influenza

Publications (1)

Publication Number Publication Date
CA3052503A1 true CA3052503A1 (en) 2018-08-16

Family

ID=63106827

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3052503A Pending CA3052503A1 (en) 2017-02-08 2018-02-07 Methods of treating influenza

Country Status (13)

Country Link
US (1) US10918623B2 (OSRAM)
EP (1) EP3579833B1 (OSRAM)
JP (1) JP7019727B2 (OSRAM)
KR (1) KR102607599B1 (OSRAM)
CN (1) CN110325187B (OSRAM)
AU (1) AU2018218179B2 (OSRAM)
BR (1) BR112019016316A2 (OSRAM)
CA (1) CA3052503A1 (OSRAM)
ES (1) ES2910136T3 (OSRAM)
MX (1) MX387115B (OSRAM)
RU (1) RU2769317C2 (OSRAM)
SG (1) SG11201907034PA (OSRAM)
WO (1) WO2018145148A1 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20130400A1 (es) 2010-07-22 2013-04-10 Gilead Sciences Inc Metodos y compuestos para tratar infecciones virales por paramyxoviridae
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
PT3349758T (pt) 2015-09-16 2022-07-13 Gilead Sciences Inc Métodos para o tratamento de infeções pelo vírus arenaviridae
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
KR20190141747A (ko) 2017-05-01 2019-12-24 길리애드 사이언시즈, 인코포레이티드 (S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
CN118766947A (zh) 2020-01-27 2024-10-15 吉利德科学公司 用于治疗SARS CoV-2感染的方法
CA3169340A1 (en) 2020-03-12 2021-09-16 Pavel R. Badalov Methods of preparing 1'-cyano nucleosides
JP7482250B2 (ja) 2020-04-06 2024-05-13 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノ置換カルバヌクレオシド類似体の吸入製剤
PL4157272T3 (pl) 2020-05-29 2025-10-20 Gilead Sciences, Inc. Remdesiwir do leczenia zakażeń wirusowych
JP2023531524A (ja) 2020-06-24 2023-07-24 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシド類似体及びその使用
CR20230100A (es) 2020-08-24 2023-04-28 Gilead Sciences Inc Compuestos fosfolípidos y usos de los mismos
LT4204421T (lt) 2020-08-27 2024-06-25 Gilead Sciences, Inc. Virusinių infekcijų gydymui skirti junginiai ir būdai
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
EP4346772A1 (en) 2021-05-26 2024-04-10 Gilead Sciences, Inc. Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
KR20240110039A (ko) * 2021-11-24 2024-07-12 바이오트론 리미티드 SARS-CoV-2 감염을 치료하는 방법
AU2023227470A1 (en) 2022-03-02 2024-08-29 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US20230295172A1 (en) 2022-03-02 2023-09-21 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
AU2023227862A1 (en) 2022-03-03 2024-09-26 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
PE20250419A1 (es) 2022-03-03 2025-02-14 Gilead Sciences Inc Compuestos antivirales y metodos de elaboracion y uso de los mismos
KR20250020476A (ko) 2022-06-06 2025-02-11 길리애드 사이언시즈, 인코포레이티드 Sars-cov-2를 포함한 바이러스성 감염을 치료하는 방법
US20240051962A1 (en) 2022-06-29 2024-02-15 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US20240043466A1 (en) 2022-06-30 2024-02-08 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
EP4665737A1 (en) 2023-02-16 2025-12-24 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
US20250084088A1 (en) 2023-08-31 2025-03-13 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
US20250090537A1 (en) 2023-08-31 2025-03-20 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
US20250099476A1 (en) 2023-09-06 2025-03-27 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
TW202517647A (zh) 2023-09-28 2025-05-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596107A (en) * 2005-06-24 2013-09-27 Biotron Ltd Antiviral compounds and methods
EP2194976B1 (en) * 2007-08-03 2015-12-09 Biotron Limited Hepatitis C antiviral compositions comprising 5-(1-methylpyrazol-4-yl)2-naphthoylguanidine and 2'-C-methyladenosine or 2'-C-methylcytidine
KR101369584B1 (ko) * 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
WO2016007538A1 (en) * 2014-07-07 2016-01-14 Prophylaxis, Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
CN110870864B (zh) 2018-08-29 2021-09-24 复旦大学 马来酸卡比沙明在制备抗流感病毒药物中的应用

Also Published As

Publication number Publication date
CN110325187B (zh) 2022-09-30
US10918623B2 (en) 2021-02-16
US20200093796A1 (en) 2020-03-26
KR102607599B1 (ko) 2023-11-28
ES2910136T3 (es) 2022-05-11
WO2018145148A1 (en) 2018-08-16
SG11201907034PA (en) 2019-08-27
EP3579833A1 (en) 2019-12-18
EP3579833B1 (en) 2022-01-05
AU2018218179B2 (en) 2023-05-04
MX2019009443A (es) 2019-12-16
KR20190112051A (ko) 2019-10-02
BR112019016316A2 (pt) 2020-03-31
RU2019126746A3 (OSRAM) 2021-05-28
EP3579833A4 (en) 2021-01-13
NZ755900A (en) 2025-03-28
AU2018218179A1 (en) 2019-08-22
RU2769317C2 (ru) 2022-03-30
JP2020506243A (ja) 2020-02-27
JP7019727B2 (ja) 2022-02-15
RU2019126746A (ru) 2021-03-09
MX387115B (es) 2025-03-19
CN110325187A (zh) 2019-10-11

Similar Documents

Publication Publication Date Title
AU2018218179B2 (en) Methods of treating influenza
Wu et al. Progress of small molecular inhibitors in the development of anti-influenza virus agents
Tarbet et al. Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice
WO2017223231A1 (en) (s)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3h-pyrazino-[1,2-b]pyridazin-yl-isobutyrate antiviral agent for use in treating influenza
Hussein et al. Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus
WO2020241759A1 (ja) インフルエンザウイルス感染症またはコロナウイルス感染症の予防および／または治療剤
WO2012142492A2 (en) Methods for inhibiting virus replication
Zhang et al. Discovery of cyperenoic acid as a potent and novel entry inhibitor of influenza A virus
US10221152B2 (en) Usage of mycophenolate mofetil or salt thereof in preparing drug for resisting against influenza virus
EP3934653B1 (en) Azelastine as antiviral treatment
CN110870864B (zh) 马来酸卡比沙明在制备抗流感病毒药物中的应用
CN118574614A (zh) 治疗sars-cov-2感染的方法
HK40017310A (en) Methods of treating influenza
HK40017310B (en) Methods of treating influenza
Pakvis Current trends of hemagglutinin and M2 protein inhibition for the treatment of influenza using antivirals
TWI530284B (zh) 馬替麥考酚酯或其鹽類用於製備抗流感病毒之藥物的用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220919

EEER Examination request

Effective date: 20220919

EEER Examination request

Effective date: 20220919

EEER Examination request

Effective date: 20220919

EEER Examination request

Effective date: 20220919